High-throughput proteomic approaches to the elucidation of potential biomarkers of chronic allograft injury (CAI)

Proteomes

Volumn 1, Issue 2, 2013, Pages 159-179

  Cassidy, Hilary ^a   Slyne, Jennifer ^a   Frain, Helena ^a   Slattery, Craig ^a   Ryan, Michael P ^a   McMorrow, Tara ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Biomarkers; Calcineurin inhibitors; Chronic allograft injury; Chronic allograft nephropathy; Cyclosporine; IF TA; Proteomics; Transplantation

Indexed keywords

EID: 84930903741     PISSN: None     EISSN: 22277382     Source Type: Journal    
DOI: 10.3390/proteomes1020159     Document Type: Review

References (75)

1. Andoh, T.F.; Bennett, W.M. Chronic cyclosporine nephrotoxicity. Curr. Opin. Nephrol. Hypertens. 1998, 7, 265-270
2. El-Zoghby, Z.M.; Stegall, M.D.; Lager, D.J.; Kremers, W.K.; Amer, H.; Gloor, J.M.; Cosio, F.G. Identifying specific causes of kidney allograft loss. Am. J. Transplant. 2009, 9, 527-535
3. Ishii, Y.; Sawada, T.; Kubota, K.; Fuchinoue, S.; Teraoka, S.; Shimizu, A. Loss of peritubular capillaries in the development of chronic allograft nephropathy. Transplant. Proc. 2005, 37, 981-983
4. Nankivell, B.J.; Chapman, J.R. Chronic allograft nephropathy: Current concepts and future directions. Transplantation 2006, 81, 643-654
5. Akalin, E.; O'Connell, P.J. Genomics of chronic allograft injury. Kidney Int. Suppl. 2010, 119, S33-S37
6. Wolfe, R.A.; Ashby, V.B.; Milford, E.L.; Ojo, A.O.; Ettenger, R.E.; Agodoa, L.Y.; Held, P.J.; Port, F.K. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N. Engl. J. Med. 1999, 341, 1725-1730
7. Suthanthiran, M.; Strom, T.B. Renal transplantation. N. Engl. J. Med. 1994, 331, 365-376
8. Textor, S.C.; Wiesner, R.; Wilson, D.J.; Porayko, M.; Romero, J.C.; Burnett, J.C., Jr.; Gores, G.; Hay, E.; Dickson, E.R.; Krom, R.A. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation 1993, 55, 1332-1339
9. Li, C.; Lim, S.W.; Sun, B.K.; Yang, C.W. Chronic cyclosporine nephrotoxicity: New insights and preventive strategies. Yonsei Med. J. 2004, 45, 1004-1016
10. Clipstone, N.A.; Crabtree, G.R. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992, 357, 695-697
11. Stepkowski, S.M. Molecular targets for existing and novel immunosuppressive drugs. In Expert Reviews in Molecular Medicine; Cambridge University Press: Cambridge, UK, 2000; Volume 2
12. Remuzzi, G.; Perico, N. Cyclosporine-induced renal dysfunction in experimental animals and humans. Kidney Int. Suppl. 1995, 52, S70-S74
13. Shihab, F.S. Cyclosporine nephropathy: Pathophysiology and clinical impact. Semin. Nephrol. 1996, 16, 536-547
14. Mihatsch, M.J.; Thiel, G.; Ryffel, B. Histopathology of cyclosporine nephrotoxicity. Transplant. Proc. 1988, 20, 759-771
15. Young, B.A.; Burdmann, E.A.; Johnson, R.J.; Alpers, C.E.; Giachelli, C.M.; Eng, E.; Andoh, T.; Bennett, W.M.; Couser, W.G. Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. Kidney Int. 1995, 48, 439-448
16. Kino, T.; Inamura, N.; Sakai, F.; Nakahara, K.; Goto, T.; Okuhara, M.; Kohsaka, M.; Aoki, H.; Ochiai, T. Effect of FK-506 on human mixed lymphocyte reaction in vitro. Transplant. Proc. 1987, 19, 36-39
17. Starzl, T.E.; Todo, S.; Fung, J.; Demetris, A.J.; Venkataramman, R.; Jain, A. FK 506 for liver, kidney, and pancreas transplantation. Lancet 1989, 2, 1000-1004
18. Cardenas, M.E.; Zhu, D.; Heitman, J. Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. Curr. Opin. Nephrol. Hypertens. 1995, 4, 472-477
19. Timmerman, L.A.; Clipstone, N.A.; Ho, S.N.; Northrop, J.P.; Crabtree, G.R. Rapid shuttling of NF-AT in discrimination of Ca 2+ signals and immunosuppression. Nature 1996, 383, 837-840
20. Sijpkens, Y.W.; Doxiadis, I.I.; van Kemenade, F.J.; Zwinderman, A.H.; de Fijter, J.W.; Claas, F.H.; Bruijn, J.A.; Paul, L.C. Chronic rejection with or without transplant vasculopathy. Clin. Transplant. 2003, 17, 163-170
21. Iwano, M.; Neilson, E.G. Mechanisms of tubulointerstitial fibrosis. Curr. Opin. Nephrol. Hypertens. 2004, 13, 279-284
22. Liu, Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J. Am. Soc. Nephrol. 2010, 21, 212-222
23. Nath, K.A. The tubulointerstitium in progressive renal disease. Kidney Int. 1998, 54, 992-994
24. Masszi, A.; Fan, L.; Rosivall, L.; McCulloch, C.A.; Rotstein, O.D; Mucsi, I.; Kapus, A. Integrity of cell-cell contacts is a critical regulator of TGF-beta 1-induced epithelial-to-myofibroblast transition: Role for beta-catenin. Am. J. Pathol. 2004, 165, 1955-1967
25. Kang, D.H.; Kanellis, J.; Hugo, C.; Truong, L.; Anderson, S.; Kerjaschki, D.; Schreiner, G.F.; Johnson, R.J. Role of the microvascular endothelium in progressive renal disease. J. Am. Soc. Nephrol. 2002, 13, 806-816
26. Marcussen, N. Atubular glomeruli in chronic renal disease. Curr. Top. Pathol. 1995, 88, 145-174
27. Strutz, F.; Zeisberg, M.; Ziyadeh, F.N.; Yang, C.Q.; Kalluri, R.; Muller, G.A.; Neilson, E.G. Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int. 2002, 61, 1714-1728
28. Eddy, A.A. Molecular insights into renal interstitial fibrosis. J. Am. Soc. Nephrol. 1996, 7, 2495-2508
29. Eddy, A.A. Progression in chronic kidney disease. Adv. Chronic Kidney Dis. 2005, 12, 353-365
30. Solez, K.; Colvin, R.B.; Racusen, L.C.; Sis, B.; Halloran, P.F.; Birk, P.E.; Campbell, P.M.; Cascalho, M.; Collins, A.B.; Demetris, A.J.; et al. Banff '05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am. J. Transplant. 2007, 7, 518-526
31. Wilkins, M.R.; Pasquali, C.; Appel, R.D.; Ou, O.; Golaz, O.; Sanchez, J.C.; Yan, J.X.; Gooley, A.A.; Hughes, G.; Humphery-Smith, I.; et al. From proteins to proteomes: Large scale protein identification by two-dimensional electrophoresis and amino acid analysis. Biotechnology (NY) 1996, 14, 61-65
32. Peng, J.; Gygi, S.P. Proteomics: The move to mixtures. J. Mass Spectrom. 2001, 36, 1083-1091
33. Naaby-Hansen, S.; Waterfield, M.D.; Cramer, R. Proteomics-Post-genomic cartography to understand gene function. Trends Pharmacol. Sci. 2001, 22, 376-384
34. Knepper, M.A. Proteomics and the kidney. J. Am. Soc. Nephrol. 2002, 13, 1398-1408
35. Lander, E.S.; Linton, L.M.; Birren, B.; Nusbaum, C.; Zody, M.C.; Baldwin, J.; Devon, K.; Dewar, K.; Doyle, M.; FitzHugh, W.; et al. Initial sequencing and analysis of the human genome. Nature 2001, 409, 860-921
36. Banks, R.E.; Dunn, M.J.; Hochstrasser, D.F.; Sanchez, J.C.; Blackstock, W.; Pappin, D.J.; Selby, P.J. Proteomics: New perspectives, new biomedical opportunities. Lancet 2000, 356, 1749-1756
37. Monteoliva, L.; Albar, J.P. Differential proteomics: An overview of gel and non-gel based approaches. Brief. Funct. Genomic Proteomic 2004, 3, 220-239
38. Silva, J.C.; Denny, R.; Dorschel, C.A.; Gorenstein, M.; Kass, I.J.; Li, G.Z.; McKenna, T.; Nold, M.J.; Richardson, K.; Young, P.; et al. Quantitative proteomic analysis by accurate mass retention time pairs. Anal. Chem. 2005, 77, 2187-2200
39. Blackburn, K.; Mbeunkui, F.; Mitra, S.K.; Mentzel, T.; Goshe, M.B. Improving protein and proteome coverage through data-independent multiplexed peptide fragmentation. J. Proteome Res. 2010, 9, 3621-3637
40. Nakorchevsky, A.; Hewel, J.A.; Kurian, S.M.; Mondala, T.S.; Campbell, D.; Head, S.R.; Marsh, C.L.; Yates, J.R., 3rd.; Salomon, D.R. Molecular mechanisms of chronic kidney transplant rejection via large-scale proteogenomic analysis of tissue biopsies. J. Am. Soc. Nephrol. 2010, 21, 362-373
41. Kurian, S.M.; Heilman, R.; Mondala, T.S.; Nakorchevsky, A.; Hewel, J.A.; Campbell, D.; Robison, E.H.; Wang, L.; Lin, W.; Gaber, L.; et al. Biomarkers for early and late stage chronic allograft nephropathy by proteogenomic profiling of peripheral blood. PLoS One 2009, 4, e6212
42. Gonyea, J.E.; Anderson, C.F. Weight change and serum lipoproteins in recipients of renal allografts. Mayo Clin. Proc. 1992, 67, 653-657
43. Perez, V.; Navarro-Munoz, M.; Bayes, B.; Lauzurica, R.; Pastor, M.C.; Troya, M.; Bonet, J.; Ibernon, M.; Navarro, M.; Serra, A.; et al. Effect of low doses of atorvastatin on the urinary peptide profile of kidney transplant patients. Transplant. Proc. 2009, 41, 2111-2114
44. Perez, V.; Navarro-Munoz, M.; Mas, S.; Bayes, B.; Pastor, M.C.; Martinez-Caceres, E.; Lauzurica, R.; Egido, J.; Romero, R. Proteomic approach to the study of statin pleiotropy in kidney transplant patients. Pharmacology 2011, 87, 161-168
45. Thongboonkerd, V.; McLeish, K.R.; Arthur, J.M.; Klein, J.B. Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int. 2002, 62, 1461-1469
46. Pieper, R.; Gatlin, C.L.; McGrath, A.M.; Makusky, A.J.; Mondal, M.; Seonarain, M.; Field, E.; Schatz, C.R.; Estock, M.A.; Ahmed, N.; et al. Characterization of the human urinary proteome: A method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1, 400 distinct protein spots. Proteomics 2004, 4, 1159-1174
47. Julian, B.A.; Suzuki, H.; Suzuki, Y.; Tomino, Y.; Spasovski, G.; Novak, J. Sources of urinary proteins and their analysis by urinary proteomics for the detection of biomarkers of disease. Proteomics Clin. Appl. 2009, 3, 1029-1043
48. Kroot, J.J.; Hendriks, J.C.; Laarakkers, C.M.; Klaver, S.M.; Kemna, E.H.; Tjalsma, H.; Swinkels, D.W. (Pre)analytical imprecision, between-subject variability, and daily variations in serum and urine hepcidin: Implications for clinical studies. Anal. Biochem. 2009, 389, 124-129
49. Bertoni, E.; Bruschi, M.; Candiano, G.; Boccardi, C.; Citti, L.; Mangraviti, S.; Rosso, G.; Larti, A.; Rosati, A.; Ghiggeri, G.M.; et al. Posttransplant proteinuria associated with everolimus. Transplant. Proc. 2009, 41, 1216-1217
50. O'Riordan, E.; Orlova, T.N.; Mendelev, N.; Patschan, D.; Kemp, R.; Chander, P.N.; Hu, R.; Hao, G.; Gross, S.S.; Iozzo, R.V.; et al. Urinary proteomic analysis of chronic allograft nephropathy. Proteomics Clin. Appl. 2008, 2, 1025-1035
51. Quintana, L.F.; Sole-Gonzalez, A.; Kalko, S.G.; Banon-Maneus, E.; Sole, M.; Diekmann, F.; Gutierrez-Dalmau, A.; Abian, J.; Campistol, J.M. Urine proteomics to detect biomarkers for chronic allograft dysfunction. J. Am. Soc. Nephrol. 2009, 20, 428-435
52. Quintana, L.F.; Campistol, J.M.; Alcolea, M.P.; Banon-Maneus, E.; Sol-Gonzalez, A.; Cutillas, P.R. Application of label-free quantitative peptidomics for the identification of urinary biomarkers of kidney chronic allograft dysfunction. Mol. Cell. Proteomics 2009, 8, 1658-1673
53. Banon-Maneus, E.; Diekmann, F.; Carrascal, M.; Quintana, L.F.; Moya-Rull, D.; Bescos, M.; Ramirez-Bajo, M.J.; Rovira, J.; Gutierrez-Dalmau, A.; Sole-Gonzalez, A.; et al. Two-dimensional difference gel electrophoresis urinary proteomic profile in the search of nonimmune chronic allograft dysfunction biomarkers. Transplantation 2010, 89, 548-558
54. Tetaz, R.; Trocme, C.; Roustit, M.; Pinel, N.; Bayle, F.; Toussaint, B.; Zaoui, P. Predictive diagnostic of chronic allograft dysfunction using urinary proteomics analysis. Ann. Transplant. 2012, 17, 52-60
55. Srivastava, M.; Eidelman, O.; Torosyan, Y.; Jozwik, C.; Mannon, R.B.; Pollard, H.B. Elevated expression levels of ANXA11, integrins beta3 and alpha3, and TNF-alpha contribute to a candidate proteomic signature in urine for kidney allograft rejection. Proteomics Clin. Appl. 2011, 5, 311-321
56. Johnston, O.; Cassidy, H.; O'Connell, S.; O'Riordan, A.; Gallagher, W.; Maguire, P.B.; Wynne, K.; Cagney, G.; Ryan, M.P.; Conlon, P.J.; et al. Identification of beta2-microglobulin as a urinary biomarker for chronic allograft nephropathy using proteomic methods. Proteomics Clin. Appl. 2011, 5, 422-431
57. Weiser, R.S.; Granger, G.A.; Brown, W.; Baker, P.; Jutila, J.; Holmes, B. Production of acute allogeneic disease in mice. Transplantation 1965, 3, 10-21
58. Pennisi, E. Genetics. The geneticist's best friend. Science 2007, 317, 1668-1671
59. Nyachieo, A.; Chai, D.C.; Deprest, J.; Mwenda, J.M.; D'Hooghe, T.M. The baboon as a research model for the study of endometrial biology, uterine receptivity and embryo implantation. Gynecol. Obstet. Invest. 2007, 64, 149-155
60. Whitworth, J.A.; Zhang, Y.; Mangos, G.; Kelly, J.J. Species variability in cardiovascular research: The example of adrenocorticotrophin-induced hypertension. Clin. Exp. Pharmacol. Physiol. 2006, 33, 887-891
61. Reuter, S.; Reiermann, S.; Worner, R.; Schroter, R.; Edemir, B.; Buck, F.; Henning, S.; Peter-Katalinic, J.; Vollenbroker, B.; Amann, K.; et al. IF/TA-related metabolic changes-Proteome analysis of rat renal allografts. Nephrol. Dial. Transplant. 2010, 25, 2492-2501
62. Klawitter, J.; Kushner, E.; Jonscher, K.; Bendrick-Peart, J.; Leibfritz, D.; Christians, U.; Schmitz, V. Association of immunosuppressant-induced protein changes in the rat kidney with changes in urine metabolite patterns: A proteo-metabonomic study. J. Proteome Res. 2010, 9, 865-875
63. O'Connell, S.; Slattery, C.; Ryan, M.P.; McMorrow, T. Identification of novel indicators of cyclosporine A nephrotoxicity in a CD-1 mouse model. Toxicol. Appl. Pharmacol. 2011, 252, 201-210
64. Zheng, M.; Lv, L.L.; Cao, Y.H.; Liu, H.; Ni, J.; Dai, H.Y.; Liu, D.; Lei, X.D.; Liu, B.C. A pilot trial assessing urinary gene expression profiling with an mRNA array for diabetic nephropathy. PLoS One 2012, 7, e34824
65. Ardaillou, R. Biology of glomerular cells in culture. Cell Biol. Toxicol. 1996, 12, 257-261
66. Wilson, P.D. In vitro methods in renal research. In Pediatric Nephrology; Springer: Berlin/Heidelberg, Germany, 2009
67. Schramek, H.; Willinger, C.C.; Gstraunthaler, G.; Pfaller, W. Endothelin-3 modulates glomerular filtration rate in the isolated perfused rat kidney. Ren. Physiol. Biochem. 1992, 15, 325-333
68. Ruegg, C.E.; Gandolfi, A.J.; Nagle, R.B.; Krumdieck, C.L.; Brendel, K. Preparation of positional renal slices for study of cell-specific toxicity. J. Pharmacol. Methods 1987, 17, 111-123
69. Smith, J.H. The use of renal cortical slices from the Fischer 344 rat as an in vitro model to evaluate nephrotoxicity. Fundam. Appl. Toxicol. 1988, 11, 132-142
70. Ruegg, C.E. Preparation of precision-cut renal slices and renal proximal tubular fragments for evaluating segment-specific nephrotoxicity. J. Pharmacol. Toxicol. Methods 1994, 31, 125-133
71. Potier, M.; L'Azou, B.; Cambar, J. Isolated glomeruli and cultured mesangial cells as in vitro models to study immunosuppressive agents. Cell Biol. Toxicol. 1996, 12, 263-270
72. Pfaller, W.; Gstraunthaler, G. Nephrotoxicity testing in vitro-What we know and what we need to know. Environ. Health Perspect. 1998, 106, 559-569
73. Lamoureux, F.; Mestre, E.; Essig, M.; Sauvage, F.L.; Marquet, P.; Gastinel, L.N. Quantitative proteomic analysis of cyclosporine-induced toxicity in a human kidney cell line and comparison with tacrolimus. J. Proteomics 2011, 75, 677-694
74. Qasim, M.; Rahman, H.; Oellerich, M.; Asif, A.R. Differential proteome analysis of human embryonic kidney cell line (HEK-293) following mycophenolic acid treatment. Proteome Sci. 2011, 9, e57
75. Puigmule, M.; Lopez-Hellin, J.; Sune, G.; Tornavaca, O.; Camano, S.; Tejedor, A.; Meseguer, A. Differential proteomic analysis of cyclosporine A-induced toxicity in renal proximal tubule cells. Nephrol. Dial. Transplant. 2009, 24, 2672-2686